SubsidieMeestersAccessible MRI
The AMRI project by CHIPIRON aims to develop an affordable, compact MRI scanner using ultra-low magnetic fields to enhance accessibility and diagnostic capabilities in underserved regions.
Projectdetails
Introduction
The AMRI (Accessible MRI) project by CHIPIRON aims to develop and commercialize a breakthrough, compact, and affordable MRI scanner operating at an ultra-low magnetic field of around 10mT. This radical innovation eliminates the need for costly, massive superconducting magnets used in standard clinical MRIs. CHIPIRON's proprietary SQUID-based detection system provides ultra-high sensitivity to enable diagnostic-quality imaging at 100-1000x lower field strength.
Objectives
The goal is to make MRI, a vital, non-invasive diagnostic tool, accessible to a much wider population, especially in developing regions and rural areas where current MRI costs and infrastructure are prohibitive. The open design of the device also accommodates patients unable to use traditional MRIs due to contraindications.
Development Progress
Led by experienced technical experts, CHIPIRON has assembled proprietary IP and demonstrated core capabilities, reaching TRL 5 thus far. The company has raised €4.3M from investors and grants.
Funding Request
CHIPIRON is requesting a €2.5M EIC Transition grant which will be followed by a request for €15M EIC Accelerator investment to complete development through regulatory approvals and market launch over 2024-2027.
Importance of EIC Support
This long-term EIC support will help derisk technical milestones and provide necessary scale-up capital. It represents an ideal public-private funding mix tailored to the needs of deep tech medtech innovation.
Conclusion
The grant and investment will catalyze CHIPIRON's progress at a crucial juncture, enabling this breakthrough deployable MRI technology to benefit healthcare systems and patients worldwide.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 2.499.999 |
Tijdlijn
| Startdatum | 1-12-2024 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CHIPIRONpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
AI-based clinical software for fully automated Cardiac Magnetic Resonance reportingAI4MedImaging is developing AI4CMR.Plus, a revolutionary software for automated cardiac assessment via CMR, aiming for a 2025 launch to enhance CVD diagnosis and improve patient outcomes. | EIC Accelerator | € 1.753.842 | 2022 | Details |
An AI powered turn-key solution for MRI based interventional cardiologyNano4Imaging aims to deliver TRACKR, a B2B platform enhancing MRI-guided interventional radiology with nano-coatings and real-time tracking software for commercial device makers. | EIC Accelerator | € 2.482.709 | 2023 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Paradigm shift in stroke: accurate diagnosis and evaluation of all treatment options in any hospital, at any timeMethinks aims to transform stroke diagnosis by enabling all hospitals to evaluate treatment options using standard imaging, reducing time-to-treatment and improving patient outcomes globally. | EIC Accelerator | € 2.495.415 | 2023 | Details |
Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgeryThericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024. | EIC Accelerator | € 2.500.000 | 2022 | Details |
AI-based clinical software for fully automated Cardiac Magnetic Resonance reporting
AI4MedImaging is developing AI4CMR.Plus, a revolutionary software for automated cardiac assessment via CMR, aiming for a 2025 launch to enhance CVD diagnosis and improve patient outcomes.
An AI powered turn-key solution for MRI based interventional cardiology
Nano4Imaging aims to deliver TRACKR, a B2B platform enhancing MRI-guided interventional radiology with nano-coatings and real-time tracking software for commercial device makers.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Paradigm shift in stroke: accurate diagnosis and evaluation of all treatment options in any hospital, at any time
Methinks aims to transform stroke diagnosis by enabling all hospitals to evaluate treatment options using standard imaging, reducing time-to-treatment and improving patient outcomes globally.
Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery
Thericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Truly portable MRI for extremity and brain imaging anywhere & everywhereThe NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally. | EIC Transition | € 2.494.415 | 2023 | Details |
MRI-scannerHet project onderzoekt de haalbaarheid van een compacte, goedkopere 3 Tesla MRI-scanner met supergeleidende magneten en stikstofkoeling. | Mkb-innovati... | € 20.000 | 2023 | Details |
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic careMIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally. | EIC Transition | € 2.495.127 | 2022 | Details |
Screening And Future Enhanced MRISAFE-MRI seeks to enhance breast cancer detection and MRI performance by implementing abbreviated screening for younger women and reducing contrast use through advanced imaging techniques. | ERC Consolid... | € 2.984.796 | 2023 | Details |
Accurate quantification of neurologic disease over timeThe project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions. | ERC Proof of... | € 150.000 | 2025 | Details |
Truly portable MRI for extremity and brain imaging anywhere & everywhere
The NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally.
MRI-scanner
Het project onderzoekt de haalbaarheid van een compacte, goedkopere 3 Tesla MRI-scanner met supergeleidende magneten en stikstofkoeling.
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care
MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.
Screening And Future Enhanced MRI
SAFE-MRI seeks to enhance breast cancer detection and MRI performance by implementing abbreviated screening for younger women and reducing contrast use through advanced imaging techniques.
Accurate quantification of neurologic disease over time
The project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions.